Boston Scientific Corporation (BSX)
BSX Price and Sentiment
BSX Latest news
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q3 2021 Results - Earnings Call Transcript
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.93 billion in Q3 of 2021, almost in line with the Wall Street estimate of $2.97 billion. Sales increased 10.3% Y/Y on a reported basis and 10.6% on an organic basis, lower than the Company's guidance of 12% - 14%.
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (NYSE:BSX) reported its Q3 earnings results on Wednesday, October 27, 2021 at 06:30 AM. Here's what investors need to know about the announcement.
Shares of Boston Scientific Corp. BSX, -0.38% rose 0.4% in premarket trading Wednesday, after the medical device company reported third-quarter profit that topped expectations, but sales that came up a bit shy, while nudging up its earnings outlook and cutting its sales growth view. The company swung to net income of $405 million, or 28 cents a share, from a loss of $169 million, or 12 cents a share, in the year-ago period.
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period.
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
Boston Scientific is scheduled to report its Q3 2021 results on Wednesday, Oct 27. We expect the company to report revenues and earnings in-line with the consensus estimates, driven by a rebound in volume of procedures performed.
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.